CNBX CNBX Pharmaceuticals Inc.
Pharmaceutical Preparations · OTC · SEC CIK 1343009 · Fiscal year ends 08/31
Financial factors as of 2026-02-28 (2026Q2), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-24.5%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE—
ROA-1,121.6%
ROIC (approx.)—
Asset turnover0.00x
Leverage & solvency
Liabilities / assets17,104.8%
Debt / equity—
Current ratio0.01x
Interest coverage-6.65x
Cash quality & payout
Operating cash flow / net income0.43x
Accruals ratio-638.0%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-05-31 | 2026Q22026-02-28 | 2026Q12025-11-30 | 2025Q4*2025-08-31 | 2025Q32025-05-31 | 2025Q22025-02-28 | 2025Q12024-11-30 | 2024Q4*2024-08-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $0 | $0 | — | — | $0 | $0 | — | — |
| Gross profit | $0 | $0 | — | — | $0 | $0 | — | — |
| R&D expense | — | $0 | $0 | $0 | $0 | $0 | $0 | -$73,934 |
| SG&A expense | $162,763 | $72,963 | $64,002 | $129,731 | $40,380 | $64,743 | $36,837 | $126,468 |
| Operating income | -$162,763 | -$72,963 | -$64,002 | -$129,731 | -$40,380 | -$64,743 | -$36,837 | -$52,533 |
| Interest expense | — | -$32,621 | $46,296 | $18,340 | $14,166 | $4,191 | $3,122 | — |
| Net income | -$154,165 | -$44,098 | -$113,719 | -$150,109 | -$59,727 | -$69,788 | -$34,352 | -$60,584 |
| EBITDA | — | — | -$64,002 | -$129,731 | -$40,380 | -$64,743 | -$36,837 | -$52,533 |
| EPS (basic) | 0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 | -0.00 | — |
| EPS (diluted) | 0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 | -0.00 | — |
| Weighted avg. shares (diluted) | 1.32B | 931.02M | 732.86M | — | 42.60M | 32.10M | 31.11M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $9,487 | $12,154 | $7,703 | $15,111 | $13,648 | $45,675 | $17,339 | $26,416 |
| Current assets | $12,795 | $14,899 | $11,162 | $18,437 | $18,615 | $50,660 | $22,308 | $31,383 |
| PP&E, net | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total assets | $12,795 | $14,899 | $11,162 | $18,437 | $18,615 | $50,660 | $22,308 | $31,383 |
| Current liabilities | $2.67M | $2.55M | $2.58M | $2.51M | $2.56M | $2.62M | $2.54M | $2.51M |
| Short-term debt | $120,000 | $75,000 | — | $0 | — | — | — | — |
| Total liabilities | $2.67M | $2.55M | $2.58M | $2.51M | $2.56M | $2.62M | $2.54M | $2.51M |
| Shareholders' equity | -$2.66M | -$2.53M | -$2.57M | -$2.50M | -$2.54M | -$2.57M | -$2.51M | -$2.48M |
| Shares outstanding | 1.48B | 1.13B | 753.20M | 553.96M | 92.51M | 33.86M | 31.11M | 31.11M |
| Cash flow statement | ||||||||
| Operating cash flow | -$47,667 | -$30,549 | -$47,408 | -$28,545 | -$52,019 | -$51,664 | -$39,077 | -$48,250 |
| Investing cash flow | — | — | $0 | $0 | $0 | $0 | $0 | $0 |
| Financing cash flow | $45,000 | $35,000 | $40,000 | $30,008 | $19,992 | $80,000 | $30,000 | $1,260 |
| Depreciation & amortization | — | — | $0 | $0 | $0 | $0 | $0 | $0 |
| Stock-based compensation | — | — | $0 | $0 | $0 | $0 | $0 | $34,975 |
Free plan shows the latest 8 periods; Pro shows all 64 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.